Atara Biotherapeutics (ATRA) Assets (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Assets for 14 consecutive years, with $21.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets fell 43.03% year-over-year to $21.0 million; the trailing twelve-month figure through Jun 2026 stood at $21.0 million (down 43.03% YoY), and the FY2025 full-year result was $20.2 million, down 81.45% from the prior year.
• Assets climbed to $21.0 million in Q2 2026 per ATRA's latest filing, from $20.0 million in the prior quarter.
• Across five years, Assets topped out at $436.1 million in Q2 2022 and bottomed at $20.0 million in Q1 2026.
• Historically, Assets has averaged $178.1 million across 5 years, with a median of $154.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Assets dropped 4.53% in 2022, then slumped 81.45% in 2025.
• Over 5 years, Assets stood at $376.4 million in 2022, then plunged by 56.03% to $165.5 million in 2023, then plunged by 34.08% to $109.1 million in 2024, then plunged by 81.45% to $20.2 million in 2025, then advanced by 3.9% to $21.0 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $21.0 million, $20.0 million, and $20.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.